KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Net Income (2016 - 2025)

Inovio Pharmaceuticals' Net Income history spans 16 years, with the latest figure at -$20.7 million for Q3 2025.

  • For Q3 2025, Net Income rose 21.27% year-over-year to -$20.7 million; the TTM value through Sep 2025 reached -$86.9 million, up 23.31%, while the annual FY2024 figure was -$107.8 million, 20.21% up from the prior year.
  • Net Income for Q3 2025 was -$20.7 million at Inovio Pharmaceuticals, up from -$22.5 million in the prior quarter.
  • Across five years, Net Income topped out at -$19.5 million in Q4 2024 and bottomed at -$108.5 million in Q2 2022.
  • The 5-year median for Net Income is -$35.5 million (2023), against an average of -$46.9 million.
  • The largest annual shift saw Net Income crashed 387.46% in 2021 before it skyrocketed 67.25% in 2023.
  • A 5-year view of Net Income shows it stood at -$106.9 million in 2021, then soared by 49.07% to -$54.5 million in 2022, then soared by 54.09% to -$25.0 million in 2023, then grew by 21.94% to -$19.5 million in 2024, then dropped by 5.85% to -$20.7 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Net Income are -$20.7 million (Q3 2025), -$22.5 million (Q2 2025), and -$24.2 million (Q1 2025).